Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM) 

Beam Therapeutics Inc. (NASDAQ:BEAM)  is among the Growth Stock Portfolio: 12 Stock Picks By Cathie Wood.

Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM) 

On January 7, 2026, TheFly reported that Bernstein maintained its Outperform rating. It increased its price objective for Beam Therapeutics Inc. (NASDAQ:BEAM) from $37 to $41. The company’s Alpha-1 Antitrypsin Deficiency program received a favorable regulatory update before the change. The latest regulatory action was Bernstein’s main stock catalyst for 2026. The company also noted several impending benchmarks, such as the anticipated release of revised AATD data in the first quarter of 2026, which are still important events to keep an eye on through the end of the year.

Separately, UBS began covering Beam Therapeutics Inc. (NASDAQ:BEAM) on January 7, 2026, with a $28 price goal and a neutral rating. The launch was a component of a larger coverage action that targeted 22 small- to mid-cap biotechnology firms. As reported by UBS, biotechnology fundamentals are starting to improve after a challenging time, and investor confidence is expected to rebound, setting the industry up for further success in 2026.

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology firm focused on developing a new class of precision genetic drugs.

While we acknowledge the risk and potential of BEAM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BEAM and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best Performing Stocks in 2025 and 12 Best Food Stocks to Buy in 2026

Disclosure: None. This article is originally published at Insider Monkey.